Home / Health / Qfitlia: A Breakthrough for Hemophilia Patients in India
Qfitlia: A Breakthrough for Hemophilia Patients in India
21 Oct
Summary
- Qfitlia therapy receives marketing authorization from India's CDSCO.
- The treatment is for adults and adolescents aged 12 and above.
- Qfitlia offers protection with as few as six injections annually.
A significant advancement in hemophilia treatment has been achieved in India with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorization for Qfitlia. This therapy, developed by Sanofi Healthcare, is designed to prevent bleeding episodes in individuals suffering from hemophilia.
The approval encompasses a broad patient demographic, including adults and adolescents aged 12 years and older. Notably, it covers individuals with or without factor VIII or IX inhibitors, marking an inclusive approach to treatment.
Qfitlia's innovative approach allows for protection with as few as six injections annually. This efficiency in dosage holds the potential to greatly enhance the accessibility of prophylaxis for patients battling Hemophilia A and Hemophilia B across India.
The therapy, known scientifically as Fitusiran, is utilized for routine prophylaxis aimed at reducing bleeding instances. This development is based on the robust data from the ATLAS phase 3 clinical program, which demonstrated effective bleed protection for patients.
